Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06005870 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 18, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 2025 to Jul 2026
    • Site contact updated
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Trial Details
NCT Number NCT06005870
Lead Sponsor Huazhong University of Science and Technology
Conditions
(from sponsor)		 Diffuse Large B Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov